First closing of $27 million Series A financing - - Fundingwill support Phase 1b/2a clinical trial of MVB-101, a prostate-specific membrane antigen x folate receptor alpha (PSMA

Australian men of all ages will soon be able to receive blood tests for prostate cancer as part of major changes to how the disease is diagnosed. Craig Watts, 61, was diagnosed with prostate cancer just four days after his mother’s funeral. He had no symptoms.

Cancer cells are remarkably good at adapting to stress. When treatments damage them, they often find new ways to survive, fueling drug resistance and disease progression.

New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.

She may still be his wife, but advanced prostate cancer can leave her feeling more like a nurse—and that painful shift is rarely discussed.

AstraZeneca’s Truqap (capivasertib) gained FDA approval, combined with abiraterone and prednisone, for treatment of certain prostate cancers.

For better cancer care in India, Novartis India has announced the launch of Pluvicto (lutetium (177Lu) vipivotide tetraxetan), the country’s first regulatory authority approved radioligand therapy for eligible patients with Prostate-Specific Membrane Antigen (PSMA)-positive prostate cancer.

Symptoms linked to urinary or sexual health often carry an element of embarrassment, making men less likely to discuss them with friends, family members, or healthcare professionals.